Introduction
Posttranscriptional gene silencing by RNA interference (RNAi) was first observed in the nematode, Caenorhabditis elegans [1] and subsequently shown to be conserved in higher eukaryotes [2, 3] . RNAi mainly involves the delivery of small interfering RNA (siRNA), which are short, double-stranded RNA molecules that are processed to 21-mers by the RNase III enzyme Dicer [4, 5] , which is loaded into the RNA-induced silencing complex (RISC) that can recognize and cleave target RNAs that are complementary to the guide strand of siRNA [6•] . siRNA molecules can be delivered as synthetic short, double-stranded molecules [7, 8] or can be expressed within the cells as individual sense and antisense strands to allow them to hybridize in vivo [9] . Another approach involves the expression of short hairpin RNA (shRNA) molecules that can be processed to 21-mer siRNA molecules [10] . Most studies have demonstrated that the expression of these molecules from constitutive RNA polymerase III xx promoters can translate to potent inhibition of HIV-1 gene expression [11] . However, there are certain drawbacks to continuous expression in that a mere seven-base complementarity to the 3' untranslated region of an unrelated mRNA molecule can silence the expression of that RNA, raising the specter of nonspecific side effects [12,13,14•] . Another cause for concern is that shRNA molecules mimic precursors of another class of small RNA molecules that use a similar biochemical pathway for export and processing and are involved in important cellular development functions [15, 16] . Thus, it becomes imperative to design expression systems that can be regulated to express in a tissue-specific or conditional manner. In this study, we developed one such shRNA expression system specific for HIV-infected cells, which the promoter uses a protein made by HIV-1, Tat, for its gene expression to turn on the anti-HIV-1 shRNA molecule, thus establishing a negative feedback loop [17••,18] .
HIV-1 transcription in cells is activated when the viral protein Tat binds to a stem loop structure at the 5' end of viral RNA called the transactivation response element (TAR). Tat recruits the positive transcriptional elongation factor B (PTEF-b), which is a heterodimer of two proteins CDK9 and cyclin T1 to polymerase, which is otherwise stalled on viral DNA due to an elongation block. This results in elongation block release and transcription activation.
Most studies examining gene expression in response to HIV infection have directly cloned the therapeutic genes under the control of the viral long terminal repeat (LTR). The drawback of extrapolating this approach to shRNA expression is that adding non-target-derived sequences to the shRNA 5' end can interfere with processing. In this scenario, the entire TAR sequence would be added on to the shRNA sequence. To address this issue, we looked at other promoters that are similarly regulated by an elongation block of the polymerase. One such promoter, the heat shock protein 70 (hsp70) promoter of Drosophila melanogaster is similarly regulated whereas activation by heat shock recruits the same PTEF-b kinase to release the elongation block.
Moreover, one can remove the heat shock elements and place other transcription factor binding sites that recruit PTEF-b and see a similar activation. Taking advantage of this similarity in activation of transcription, we designed a chimeric promoter such that the HIV-1 LTR, up to and including the TAR element, was placed immediately upstream of the core hsp70 promoter in place of the heat shock elements [17••,18] (Fig. 1) . The shRNA sequence, along with a minimal polyA sequence for termination, is placed under the hsp70 promoter such that transcription of shRNA begins from +1, and no extra sequences are added on to the shRNA. Such an arrangement would result in transcription initiation from both the LTR and the hsp70 promoter with the TAR loop formed in between the two promoters. In the presence of virus, Tat would be produced, which would recruit PTEF-b and bind to the TAR element and activate transcription from both promoters. The transcription from the hsp70 promoter would synthesize shRNA molecules that can be processed to 21-mer siRNA molecules and mediate inhibition of HIV-1. In absence of the virus or when the viral transcription has been inhibited, the system would again become silent.
The above-mentioned construct was tested for both its activation in the presence of Tat supplied in trans or infectious virus and the ability of the synthesized siRNA to inhibit the virus. The HIV-1-inducible shRNA expressing DNA vector was introduced (transfected) along with the infectious proviral DNA or the DNA encoding the viral protein Tat into human embryonic kidney cell line 293 (HEK 293). Culture supernatant was collected every 24 hours and assayed for the viral protein p24 as an index of viral inhibition. Seventy-two hours post-transfection, the HEK293 cells were harvested and total RNA from the cells was extracted and probed for expression of siRNA in response to Tat or the proviral DNA.
To test the system in a more stable, long-term gene therapy setting, the HIV-1-inducible shRNA-expressing DNA was placed in a lentiviral vector backbone and introduced (transduced) into a T-cell line (CEM T cells) or primary CD34 stem cells, which are progenitor cells for macrophages. The lentiviral vector carrying the therapeutic shRNA integrates into the genome of the cell and can then be stably maintained and is ready to respond when the virus enters the cells. CEM T cells were then infected with the IIIB strain of the virus (T-cell tropic) and CD34 cells with the JRFL strain (macrophage tropic). On designated days, the culture supernatant was collected and assayed for viral p24 protein.
Results
Expression and processing of shRNA to 21-mer siRNA products were only observed when the cells were transfected with the DNA encoding the viral protein Tat or in the presence of the infectious proviral DNA [17••,18] . The p24 assay of culture supernatants from cells co-transfected with the HIV-inducible shRNA construct and the proviral DNA demonstrated approximately 90% inhibition of HIV-1 72 hours post-transfection. In this case, viral DNA enters the cell and encodes Tat for its own replication. Instead, Tat protein also turns on shRNA expression, which inhibits the virus. Moreover, the expression of active siRNA occurs only from the hsp70 promoter and not from the LTR-derived transcripts as mutating the hsp70 promoter so as to render it inactive resulted in complete shutdown of shRNA expression and processing. By reverse transcriptase polymerase chain reaction, we were able to detect RNA from both promoters, suggesting that placing these two promoters in close proximity does not interfere with each other. However, only the hsp70-derived transcripts were processed to siRNA.
CEM T cells or CD34 cells stably expressing the inducible shRNA construct were able to inhibit viral replication up to 80% when compared with cells transduced with a dummy lentiviral vector, suggesting that this approach can be employed for long-term gene therapy protocols.
Conclusions
RNAi is a potent inhibitor of targeted gene expression in a wide variety of organisms [1, 19, 20] . The triggers for RNAi are siRNAs that are processed from long, double-stranded or hairpin RNA precursors and become part of a ribonucleoprotein complex [21, 22] . In an effort to create an inducible system that would respond to HIV infection, we placed HIV-1 LTR, up to and including the TAR element, upstream of the core hsp70 promoter. Both HIV-1 LTR and hsp70 promoters are similarly regulated and require PTEF-b for release of elongation block and activation of transcription [23, 24] . Our design assumed that transcription from the viral LTR would result in TAR loop formation to which Tat would bind and recruit PTEF-B. This, in turn, would promoter. In absence of the viral transactivator Tat, polymerase (Pol) from the LTR initiated and hsp70-initiated transcript pauses due to an elongation block. When the virus infects the cell, Tat is produced, which then recruits a cellular protein complex called positive transcriptional elongation factor B (PTEF-b) which phosphorylates the C-terminal domain of the stalled polymerase and makes it elongation competent. Short hairpin RNA (shRNA) is made only from the hsp70-initiated transcript. mpolyA-minimal polyadenylation recognition and cleavage element; TBP-TATA-binding protein.
